Celltrion is intensifying its efforts to penetrate the Japanese allergy treatment market.
The company announced on October 3 that it will promote the clinical evidence and competitiveness of its omalizumab biosimilar, Omilclo, at the World Allergy Congress (WAC 2026) taking place from October 15 to 18 at the Kyoto International Conference Center. Celltrion will also host a seminar for over 400 local medical professionals.
At the congress, Celltrion plans to operate a corporate booth to introduce Omilclo's clinical data, product competitiveness, and global production and supply capabilities.
On the second day of the congress, October 16, the company will hold a seminar titled "Expanding Treatment Options Through Biosimilars: The Future of Asthma and Allergic Rhinitis Treatment." Celltrion aims to share clinical experiences with omalizumab and the value of biosimilars with the attending medical professionals.
Omilclo is a biosimilar of the allergy treatment Xolair (active ingredient omalizumab). Celltrion received product approval in Japan in March for three indications: bronchial asthma, chronic idiopathic urticaria, and seasonal allergic rhinitis, and is preparing for local launch following price registration.
Notably, Omilclo is the first omalizumab biosimilar approved in Japan, and Celltrion is leveraging its first-mover advantage to capture the initial market share. The product has also received approval for convenient administration forms, including pre-filled syringes and auto-injectors.
Having already established a presence in the Japanese market with biosimilars for autoimmune diseases and cancer treatments, Celltrion plans to utilize its existing direct sales infrastructure for the launch of Omilclo.
According to market research firm IQVIA, the infliximab biosimilar Remsima held a 48% market share in Japan as of July, ranking first, while the adalimumab biosimilar Yuflyma led with a 21% share. The market shares for cancer treatments Herceptin and Vegzelma were 78% and 64%, respectively.
Omilclo was first launched in Europe in September of last year and recorded a 21% market share in Europe as of the first quarter of this year. Global sales reached 188.4 billion won in the first half of this year. Following its launch in the U.S. on October 5, the company is expanding its growth momentum with the upcoming entry into Japan.
A Celltrion official stated, "We will work to establish Omilclo in the market based on the trust and direct sales infrastructure built by our existing products in Japan."
Meanwhile, Celltrion is also accelerating its performance growth. The company reported preliminary consolidated revenues of 1.5 trillion won and an operating profit of 510 billion won for the third quarter, as announced the previous day. Compared to the same period last year, revenues increased by 45.8%, and operating profit rose by 69.2%. The operating profit margin improved by 4.7 percentage points to 34%.
Both revenue and operating profit reached record highs for a single quarter, driven by an increase in the sales proportion of high-margin follow-up products and cost improvements, with quarterly operating profit surpassing 500 billion won for the first time since the company's establishment.
The company announced on October 3 that it will promote the clinical evidence and competitiveness of its omalizumab biosimilar, Omilclo, at the World Allergy Congress (WAC 2026) taking place from October 15 to 18 at the Kyoto International Conference Center. Celltrion will also host a seminar for over 400 local medical professionals.
At the congress, Celltrion plans to operate a corporate booth to introduce Omilclo's clinical data, product competitiveness, and global production and supply capabilities.
On the second day of the congress, October 16, the company will hold a seminar titled "Expanding Treatment Options Through Biosimilars: The Future of Asthma and Allergic Rhinitis Treatment." Celltrion aims to share clinical experiences with omalizumab and the value of biosimilars with the attending medical professionals.
Omilclo is a biosimilar of the allergy treatment Xolair (active ingredient omalizumab). Celltrion received product approval in Japan in March for three indications: bronchial asthma, chronic idiopathic urticaria, and seasonal allergic rhinitis, and is preparing for local launch following price registration.
Notably, Omilclo is the first omalizumab biosimilar approved in Japan, and Celltrion is leveraging its first-mover advantage to capture the initial market share. The product has also received approval for convenient administration forms, including pre-filled syringes and auto-injectors.
Having already established a presence in the Japanese market with biosimilars for autoimmune diseases and cancer treatments, Celltrion plans to utilize its existing direct sales infrastructure for the launch of Omilclo.
According to market research firm IQVIA, the infliximab biosimilar Remsima held a 48% market share in Japan as of July, ranking first, while the adalimumab biosimilar Yuflyma led with a 21% share. The market shares for cancer treatments Herceptin and Vegzelma were 78% and 64%, respectively.
Omilclo was first launched in Europe in September of last year and recorded a 21% market share in Europe as of the first quarter of this year. Global sales reached 188.4 billion won in the first half of this year. Following its launch in the U.S. on October 5, the company is expanding its growth momentum with the upcoming entry into Japan.
A Celltrion official stated, "We will work to establish Omilclo in the market based on the trust and direct sales infrastructure built by our existing products in Japan."
Meanwhile, Celltrion is also accelerating its performance growth. The company reported preliminary consolidated revenues of 1.5 trillion won and an operating profit of 510 billion won for the third quarter, as announced the previous day. Compared to the same period last year, revenues increased by 45.8%, and operating profit rose by 69.2%. The operating profit margin improved by 4.7 percentage points to 34%.
Both revenue and operating profit reached record highs for a single quarter, driven by an increase in the sales proportion of high-margin follow-up products and cost improvements, with quarterly operating profit surpassing 500 billion won for the first time since the company's establishment.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.